Tampere University of Technology

TUTCRIS Research Portal

No additional benefit of adding ifosfamide to docetaxel in castration-resistant metastatic prostate cancer

Research output: Contribution to journalArticleScientificpeer-review

Details

Original languageEnglish
Pages (from-to)3305-3310
Number of pages6
JournalAnticancer Research
Volume32
Issue number8
Publication statusPublished - Aug 2012
Publication typeA1 Journal article-refereed

Abstract

Background: In the treatment of many types of cancer, combination chemotherapy has been shown to be better than single-agent chemotherapy. The aim of our phase I-II clinical trial was to assess the efficacy and toxicity of docetaxel-ifosfamide combination chemotherapy in patients with castration-resistant metastatic prostate cancer (CRPC). Patients and Methods: A total of 31 patients were enrolled to receive first-line chemotherapy consisting of 40-60 mg/m2 docetaxel followed by 3.0 g/ m2 ifosfamide with mesna. All drugs were administered intravenously. The maximum duration of the chemotherapy was six cycles. The median age of the patients was 70 (range 58-82) years. Prostate specific antigen (PSA) responses were determined according to the PSA working group guidelines and all toxicities, time-to-progression and overall survival were determined according to the WHO criteria. Results: The objective PSA response rate was 32% in 11/31 patients. The mean PSA value at baseline was 300 (range 2.5-1577) μg/l. The overall median survival was 14.1 months; 15 patients were alive at a median follow-up time of 18 months. The observed side-effects were as expected, with grade 3-4 neutropenia developing in 38% of the cycles, whereas febrile neutropenia occurred in only 12% of the patients. The median number of administered cycles was 4.8. No acute hypersensitivity reactions were observed. Transient renal insufficiency developed in two patients, thus necessitating dose reductions. Conclusion: The combination of docetaxel and ifosfamide seems to be well-tolerated and has some activity in patients with CRPC. However, newer docetaxel-based combination chemotherapy regimens need to be further developed in other to provide more efficacious and well-tolerated treatment options for earlier phases of CRPC.

ASJC Scopus subject areas

Keywords

  • Androgen-independent, Combination chemotherapy, Docetaxel, Ifosfamide, Metastatic, Prostate cancer